SoftOx remains a highly speculative, pre-revenue biotech. While clinical progress is evident, the relentless dilution from the Long State financing facility creates a massive overhang that severely limits per-share upside for retail investors. The current price is essentially a function of capital market supply/demand rather than fundamental value.
Price Movement
Price and Stoxie target over time
SoftOx remains a highly speculative, pre-revenue biotech. While clinical progress is evident, the relentless dilution from the Long State financing facility creates a massive overhang that severely limits per-share upside for retail investors. The current price is essentially a function of capital market supply/demand rather than fundamental value.
Sentiment
Sentiment from official company announcements and reports.
The voice of retail investors and social media chatter.
39 threads
Sentiment from news across the company's specific industry.
0 articles
Sentiment from news across the broader market sector.
0 articles
Financial Hub
Market cap
$318.66M
P/E ratio
5.90
Div. yield
N/A
Quarterly EPS Surprise
Comparing actual earnings to analysts' estimates.